Vertex Pharmaceuticals Inc (MIL:1VRTX)
€ 436.75 0 (0%) Market Cap: 114.49 Bil Enterprise Value: 109.92 Bil PE Ratio: 0 PB Ratio: 7.74 GF Score: 72/100

Vertex Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 15, 2022 / 08:20PM GMT
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good afternoon, everyone. Thanks for joining us. Really pleased to have Vertex with us today, and we have CEO, Reshma Kewalramani. With that, Reshma, I'm going to open it up to you if you have any opening comments, and then we can jump into questions.

Reshma Kewalramani
Vertex Pharmaceuticals Incorporated - CEO, President & Director

Sounds good. Salveen, thanks so much for the invitation. It's so good to be in person and in real life without a screen in front of us.

I wanted to make a couple of opening comments. The first was to say, I will make some forward-looking statements, and I refer you to our SEC disclosures to look through all of the risks. Maybe to start with Salveen, a couple of points about where we are as a company.

Vertex is at a new inflection point today with clear sustained leadership in CF, a pipeline that is broad and advanced with 5 programs that are now post proof of concept and a balance sheet that is strong and growing and allows us to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot